FDA greenlights generics of Novartis' $3B MS star Gilenya amid legal fight

6th December 2019 Uncategorised 0

In June, a U.S. district court judge temporarily shielded Novartis’ $3 billion-a-year multiple sclerosis drug Gilenya from generic competition—but that’s not preventing generics makers from lining up at the starting gate. Thursday, the FDA approved the first three generic versions of Gilenya, which will be made by HEC Pharm, Biocon and Sun Pharmaceutical.

More: FDA greenlights generics of Novartis' B MS star Gilenya amid legal fight
Source: fierce